Literature DB >> 17671399

Investigation of vascular endothelial growth factor gene polymorphisms and its association with clinicopathologic characteristics in gastric cancer.

Yee Soo Chae1, Jong Gwang Kim, Sang Kyun Sohn, Yoon Young Cho, Joon Ho Moon, Han-Ik Bae, Jae Yong Park, Myung-Hoon Lee, Hyun-Chul Lee, Ho Young Chung, Wansik Yu.   

Abstract

OBJECTIVE: Vascular endothelial growth factor (VEGF) is known to be a potent proangiogenic factor. This study evaluates the potential association of three VEGF gene polymorphisms (-460T > C, +405G > C, and 936C > T) with the susceptibility to and clinicopathologic characteristics of gastric cancer.
METHODS: The VEGF genotypes were determined using paraffin-embedded tissue from 413 patients who underwent a surgical resection and peripheral blood lymphocytes from 413 healthy controls by PCR-RFLP assay.
RESULTS: There was no difference in the allele frequency of -460T > C polymorphism. However, for the +405G > C polymorphism, the +405C allele was associated with a significantly decreased susceptibility to gastric cancer [odds ratio (OR) 0.686; 95% confidence interval (CI) 0.564-0.834]. Although there was no significant difference in the distribution of the 936C > T polymorphism between the two groups, the 936T allele was associated with a decreased susceptibility to gastric cancer (OR 0.757; 95% CI 0.591-0.970). In the haplotype analyses, the haplotype TCT (OR 0.405; 95% CI 0.263-0.624) was most closely associated with a decreased susceptibility to gastric cancer. However, no significant association was observed between the frequency of the genotypes or alleles and the clinicopathologic characteristics of gastric cancer.
CONCLUSION: These observations imply that the VEGF gene polymorphisms may be associated with the susceptibility to gastric cancer. However, further studies of other VEGF sequence variants and their biological functions are needed to understand the role of the VEGF polymorphisms in determining the susceptibility to gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17671399     DOI: 10.1159/000106788

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  20 in total

1.  VEGF +936C/T and +460C/T gene polymorphisms and oral cancer risk: a meta-analysis.

Authors:  Su-Feng Zhao; Ping Zhan; Xu-Dong Yang; Ming-Xing Lu; Guo-Wen Sun; Yu-Xin Wang; Yin-Kai Zhang; Yu-Mei Pu; En-Yi Tang
Journal:  Mol Biol Rep       Date:  2013-09-22       Impact factor: 2.316

2.  Vascular endothelial growth factor gene polymorphism (-634G/C) and breast cancer risk.

Authors:  Weirong Yao; Rongzeng Yan; Lin Ma; Huiping Wan; Yanmin Yu; Xia Cheng; Yingliang Li
Journal:  Tumour Biol       Date:  2014-05-10

3.  Current evidences on vascular endothelial growth factor polymorphisms and breast cancer susceptibility.

Authors:  Li-Xin Qiu; Ke Wang; Sheng Yang; Chen Mao; Lei Zhao; Lei Yao; Jian Zhang; Qun-Ling Zhang; Si Sun; Kai Xue
Journal:  Mol Biol Rep       Date:  2010-12-02       Impact factor: 2.316

4.  Vascular endothelial growth factor +936C/T polymorphism and gastric cancer risk: A meta-analysis.

Authors:  Li-Ping Zhou; Hong Luan; Xin-Hua Dong; Guo-Jiang Jin; Dong-Liang Man; Hong Shang
Journal:  Exp Ther Med       Date:  2011-05-31       Impact factor: 2.447

5.  Meta-analysis of the association between VEGF-634 G>C and risk of malignancy based on 23 case-control studies.

Authors:  Liu Liu; Lin Liu; Fei Zeng; Kai Wang; Jun Huang; Lin Xin; Pei-Qian Zhu
Journal:  J Cancer Res Clin Oncol       Date:  2010-12-21       Impact factor: 4.553

6.  Association between vascular endothelial growth factor +936C/T polymorphism and breast cancer risk: a meta-analysis of 18 case-control studies.

Authors:  Danhui Huang; Jianhua Wu; Zhenya Sun; Senlin Huang; Yuzhao Zhang; Lingling Wang; Tao Zeng
Journal:  Int J Mol Epidemiol Genet       Date:  2016-09-30

7.  Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

Authors:  Bryan P Schneider; Molin Wang; Milan Radovich; George W Sledge; Sunil Badve; Ann Thor; David A Flockhart; Bradley Hancock; Nancy Davidson; Julie Gralow; Maura Dickler; Edith A Perez; Melody Cobleigh; Tamara Shenkier; Susan Edgerton; Kathy D Miller
Journal:  J Clin Oncol       Date:  2008-10-01       Impact factor: 44.544

8.  Polymorphism of VEGF-460C/T associated with the risk and clinical characteristics of lung cancer in Chinese population.

Authors:  Shi-Fang Sun; Da-Bing Huang; Chao Cao; Zai-Chun Deng
Journal:  Med Oncol       Date:  2013-01-04       Impact factor: 3.064

9.  VEGF -460C>T polymorphism and cancer risk: a meta-analysis.

Authors:  Bin Xu; Ning-Han Feng; Na Tong; Zi-Dun Wang; Wei Zhang; Hong-Fei Wu; Lin-Xin Hua
Journal:  Med Oncol       Date:  2009-10-09       Impact factor: 3.064

10.  The VEGF -634G>C promoter polymorphism is associated with risk of gastric cancer.

Authors:  Xiaoxiang Guan; Hui Zhao; Jiangong Niu; Dongfeng Tang; Jaffer A Ajani; Qingyi Wei
Journal:  BMC Gastroenterol       Date:  2009-10-16       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.